RYTM - Rhythm Pharmaceuticals beats Q4 top and bottom line estimates; initiates FY23 outlook

• Rhythm Pharmaceuticals press release ( NASDAQ: RYTM ): Q4 GAAP EPS of -$0.75 beats by $0.07 .
• Revenue of $8.8M (+383.5% Y/Y) beats by $1.64M .
• As of December 31, 2022, cash, cash equivalents and short-term investments were approximately $333.3 million, as compared to $294.9 million as of December 31, 2021.
• Financial Guidance: Rhythm today announced that, for the year ending December 31, 2023, it currently anticipates approximately $200 million to $220 million in Non-GAAP Operating Expenses, comprised of $120 million to $130 million from R&D expenses and $80 million to $90 million from S,G&A expenses.

• Based on its current operating plans, Rhythm expects that its existing cash, cash equivalents and short-term investments as of December 31, 2022 will be sufficient to fund its operating expenses and capital expenditure requirements into 2025.

For further details see: